Mode
Text Size
Log in / Sign up

Prehabilitation program improves physical and psychological outcomes in leukemia patients before chemotherapyGetting Ready Before Chemotherapy Starts May Change How You Come Through It

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider prehabilitation as a safe, feasible intervention with potential multi-domain benefits in leukemia patients, but evidence remains preliminary.

This single-blind, parallel-group randomized controlled trial enrolled 86 newly diagnosed leukemia patients at a tertiary hospital in China. Participants were assigned to either a 12-week trifold prehabilitation program (integrating exercise, nutritional support, and psychological care) prior to induction chemotherapy or to usual care. The primary outcomes were feasibility metrics, with secondary outcomes assessing physical, nutritional, and psychological status at baseline, pre-chemotherapy, and 1 and 3 months post-chemotherapy.

The study reported a recruitment rate of 60.14% and an attrition rate of 20.93%. Compared to usual care, the prehabilitation group showed significantly greater improvements in 6-minute walk distance from pre-chemotherapy to 3 months post-chemotherapy (p < 0.05). Cancer-related fatigue also showed significantly greater improvement over the same period (p < 0.05). Nutritional status improved at 3 months post-chemotherapy (p = 0.033). Anxiety and depression scores were consistently lower across all follow-up points in the intervention group (p < 0.01). Exercise self-efficacy showed significant improvements at 1 and 3 months post-chemotherapy.

No serious adverse events occurred, though detailed adverse event and tolerability data were not reported. Key limitations include the single-center design, small sample size, and lack of reported effect sizes or absolute numbers for most outcomes. Funding sources and conflicts of interest were not reported.

For practice, this RCT provides preliminary evidence that a structured prehabilitation program is safe and feasible for leukemia patients and may offer benefits across multiple domains. However, the generalizability is limited by the single-center Chinese setting and small sample. The findings support further investigation of prehabilitation in this population but do not yet justify widespread implementation outside of a research context.

What Happens to the Body Before Chemotherapy Even Starts

Most conversations about cancer treatment focus on what happens during and after chemotherapy. But the weeks before treatment begins matter too — sometimes more than people realize.

Leukemia patients heading into induction chemotherapy (the intense first phase of treatment) often start in a physically depleted state. The disease itself has already been taxing the body. Add fear, disrupted sleep, and nutritional changes, and many patients arrive at day one of chemotherapy already struggling.

The Gap in Standard Care

Standard care before chemotherapy tends to be focused on logistics — blood tests, insurance, medication schedules. Physical conditioning, mental health support, and nutrition planning are often addressed reactively, if at all.

But in other surgical specialties — orthopedics, cardiac surgery — "prehabilitation" has become an established concept. The idea is to optimize a patient's physical and psychological state before a major medical event, so they're better equipped to handle and recover from it.

No one had rigorously tested whether that same logic applied to leukemia chemotherapy.

Three Pillars Before Treatment Begins

Researchers at a hospital in China enrolled 86 newly diagnosed leukemia patients and randomly assigned them to either a 12-week prehabilitation program or standard care.

The program had three components: structured exercise sessions (building toward cardiopulmonary fitness), individualized nutritional guidance, and psychological support addressing the emotional burden of a new cancer diagnosis. Think of it like renovating a house before a storm — rather than trying to make repairs in the middle of it.

What the Trial Measured

Patients were assessed at four points: before the program, at the start of chemotherapy, one month after chemotherapy, and three months after chemotherapy. Researchers tracked walking endurance (using a 6-minute walk test), cancer-related fatigue, anxiety and depression scores, and nutritional status.

What Changed — and When

The prehabilitation group walked further and reported less fatigue than the control group at every follow-up point after chemotherapy began. The improvement in walking distance and fatigue reduction were statistically significant and held through three months post-treatment.

Anxiety and depression levels were consistently lower in the prehabilitation group at every single follow-up time point. Nutritional status improved by three months post-chemotherapy, though it took longer to show up than some of the other benefits.

This Is Where Things Get Interesting

The study found no serious adverse events in the prehabilitation group — meaning the exercise and support program didn't cause harm, even in patients about to undergo aggressive chemotherapy.

That's an important baseline question: was it even safe? The answer appears to be yes.

What This Tells Us About Timing

Cancer care specialists have increasingly argued that treatment outcomes depend not just on the drugs given but on the patient's state going into treatment. A patient who starts chemotherapy with better cardiovascular fitness may handle the physical toll more effectively. A patient with lower anxiety may adhere better to the treatment protocol.

This trial adds real data to that argument.

If you or a family member has been diagnosed with leukemia and is waiting to begin chemotherapy, this research suggests that using that window proactively — with guided exercise, nutritional support, and mental health resources — may produce real benefits. Talk to your oncology team about whether a structured prehabilitation plan is available or appropriate.

Prehabilitation programs are not yet standard in most leukemia care settings, and this trial was small. But the evidence strongly supports asking your care team about what preparation is available.

Limitations to Keep in Mind

This was a single-center trial with 86 patients, and roughly 21% dropped out before completing the study. The trial was conducted in China at a tertiary hospital, so resources and patient populations may differ from other settings. The prehabilitation program was also multifaceted, making it hard to determine which component — exercise, nutrition, or psychological care — drove the benefits.

Larger multicenter trials are needed to validate these findings across different leukemia types and treatment centers. Researchers are also investigating whether a shorter or more targeted version of prehabilitation could deliver comparable benefits, making it feasible for patients who don't have twelve weeks before their first chemotherapy cycle.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up2.8 mo
PublishedApr 2026
View Original Abstract ↓
PURPOSE: A trifold prehabilitation program that integrates exercise, nutritional support, and psychological care has not yet been incorporated into routine care for leukemia patients prior to induction chemotherapy. This study aimed to evaluate the safety and feasibility of this trifold intervention and to further examine its potential impact on physical fitness, nutritional risk, and psychological health. METHODS: In a single-blind, parallel-group randomized trial, 86 newly diagnosed leukemia patients at a tertiary hospital in China were randomly assigned to a 12-week prehabilitation group (n = 43) or usual care (n = 43). Primary outcomes were recruitment, attrition, and safety. Secondary outcomes included the 6-min walk test (6MWT), exercise self-efficacy, cancer-related fatigue (CRF), anxiety, depression, and nutrition. Assessments occurred at baseline (T0), pre-chemotherapy (T1), and 1 (T2) and 3 months (T3) post-chemotherapy. RESULTS: The recruitment rate was 60.14%, with an attrition rate of 20.93%, and no serious adverse events occurred. Compared with controls, the intervention group showed significantly greater improvements in 6-min walk distance and cancer-related fatigue from T1 to T3 (all p < 0.05). Improvements in exercise self-efficacy were significant at T2 and T3 but not at T1. Nutritional status improved at T3 (p = 0.033). Anxiety and depression levels were consistently lower across all follow-up points (p < 0.01). CONCLUSIONS: This study demonstrates that prehabilitation is safe, feasible, and potentially beneficial for physical, nutritional, and psychological outcomes in leukemia patients. TRIAL REGISTRATION: China Clinical Trials Registration Platform: ChiCTR2500105061, date of registration: June 27, 2025 (retrospectively registered).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.